Article ID Journal Published Year Pages File Type
2479251 Drug Metabolism and Pharmacokinetics 2010 8 Pages PDF
Abstract

Summary:Unglycosylated recombinant human α1-acid glycoprotein (hAGP) variants (rF1*S and rA) were prepared in an E. coli expression system using the Origami B strain and pET-3c vector. Thioredoxin was co-expressed to promote the appropriate folding of hAGP. SDS-PAGE under reducing conditions showed that rF1*S and rA migrate as single bands after purification. However, several bands derived from rA were observed under non-reducing conditions because of the high reactivity of a free cystein residue (C149). We therefore prepared a mutant of A variant (C149R-A), and confirmed that this mutant maintained homogeneity. Circular dichroism and intrinsic tryptophan fluorescence spectroscopic analyses indicated that rF1*S and C149R-A have almost the same conformational structures as F1*S and A purified from serum. Ligand binding experiments using propranolol as a F1*S ligand and disopyramide as an A specific ligand indicated that the capacity of rF1*S and C149R-A is equivalent to those ligands as well as F1*S and A from serum. These results suggest that the oligosaccharide moieties of hAGP have negligible effects on the structural and ligand binding properties of hAGP. Thus, rF1 *S and C149R-A promise to be useful in studies on the drug binding sites of hAGP.

Related Topics
Health Sciences Pharmacology, Toxicology and Pharmaceutical Science Drug Discovery